Growth Metrics

TriSalus Life Sciences (TLSI) Cash from Investing Activities (2022 - 2026)

TriSalus Life Sciences has reported Cash from Investing Activities over the past 5 years, most recently at -$141000.0 for Q1 2026.

  • For Q1 2026, Cash from Investing Activities rose 80.25% year-over-year to -$141000.0; the TTM value through Mar 2026 reached -$265000.0, up 73.31%, while the annual FY2025 figure was -$838000.0, 142.9% down from the prior year.
  • Cash from Investing Activities for Q1 2026 was -$141000.0 at TriSalus Life Sciences, down from -$41000.0 in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $93000.0 in Q2 2025 and troughed at -$1.6 million in Q3 2022.
  • A 5-year average of -$276352.9 and a median of -$74000.0 in 2023 define the central range for Cash from Investing Activities.
  • On a YoY basis, Cash from Investing Activities climbed as much as 255.0% in 2025 and fell as far as 981.82% in 2025.
  • Year by year, Cash from Investing Activities stood at -$272000.0 in 2022, then tumbled by 36.76% to -$372000.0 in 2023, then soared by 86.56% to -$50000.0 in 2024, then increased by 18.0% to -$41000.0 in 2025, then plummeted by 243.9% to -$141000.0 in 2026.
  • Business Quant data shows Cash from Investing Activities for TLSI at -$141000.0 in Q1 2026, -$41000.0 in Q4 2025, and -$176000.0 in Q3 2025.